White House budget includes ambitious push to eliminate hepatitis C | Science | AAAS

日本 ニュース ニュース

White House budget includes ambitious push to eliminate hepatitis C | Science | AAAS
日本 最新ニュース,日本 見出し
  • 📰 NewsfromScience
  • ⏱ Reading Time:
  • 65 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 29%
  • Publisher: 51%

The Biden administration's fiscal year 2024 budget proposal aims to eliminate hepatitis C from the United States by creating a nationwide program to fight the disease.

“The field has been waiting for this for a long time,” says transplant hepatologist David Kaplan of the University of Pennsylvania Perelman School of Medicine. Eliminating the disease “is possible and feasible,” he says, noting that other countries are on their way to meeting that goal. But that doesn’t mean the effort will be easy, adds pediatric hepatologist James Squires of the UPMC Children’s Hospital of Pittsburgh. “It will be a challenge.

Despite the lack of a vaccine, researchers can talk seriously about eliminating hepatitis C because the drugs known as direct-acting antivirals , first approved in the United States in 2013, are so effective. These drugs, such as the combination of sofosbuvir and ledipasvir sold as Harvoni, can oust the virus from more than 95% of patients with only an 8- to 12-week course of treatment.

For example, estimates suggest about 10% of the roughly 2 million people in the United States who are in jail or prison carry the virus, but they often go without testing and treatment. For this group, “We need more resources for testing and a cultural shift in availability of treatment,” says Matthew Akiyama, a clinician-investigator at the Albert Einstein College of Medicine.

The initiative would also tackle one of the biggest treatment obstacles—drug costs. Although the price of DAAs has fallen by about 75% since they were introduced, a full course still runs about $20,000. To improve treatment for incarcerated people and other underserved populations, the program would adopt the so-called subscription, or Netflix, model, first tested by Louisiana, in which the government pays drug companies a set amount for as much drug as it needs, rather than paying per dose.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

NewsfromScience /  🏆 515. in US

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Geneticists should rethink how they use race and ethnicity, panel urges | Science | AAAS
続きを読む »

MRI for all: Cheap portable scanners aim to revolutionize medical imaging | Science | AAASMRI for all: Cheap portable scanners aim to revolutionize medical imaging | Science | AAAS
続きを読む »

This sea slug cut off its own head—and lived to tell the tale | Science | AAAS
続きを読む »

Startups try to turn laser fusion success into clean power plants | Science | AAAS
続きを読む »

Alpaca-derived antibodies could protect plants from disease | Science | AAAS
続きを読む »

Ancient DNA upends European prehistory | Science | AAAS
続きを読む »



Render Time: 2025-03-01 22:42:42